6月11日 - ** 药物开发商Vaxart VXRT.O股价盘前上涨81.2%至71美分
** 该公司称， (link)，其新型实验性诺如病毒疫苗在早期试验中产生的免疫反应明显强于原版疫苗
** VXRT 称，第二代疫苗对一种诺如病毒株的保护性抗体增加了 141%，对另一种病毒株的保护性抗体增加了 94
** 该公司声称，即使剂量较低，新疫苗也比 VXRT 的原版疫苗效果更好，而且所有测试疫苗的耐受性都很好，没有出现严重的副作用
** 截至上一交易日收盘，VXRT 股价累计下跌 40.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.